Livforsakringsbolaget Skandia Omsesidigt Invests $532,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,600 shares of the company’s stock, valued at approximately $532,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp grew its stake in shares of Medpace by 7.2% during the 3rd quarter. State Street Corp now owns 752,957 shares of the company’s stock valued at $251,337,000 after buying an additional 50,312 shares during the period. Geode Capital Management LLC grew its position in Medpace by 7.6% during the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock valued at $209,885,000 after acquiring an additional 44,371 shares during the period. Wellington Management Group LLP increased its stake in Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after acquiring an additional 109,886 shares during the last quarter. American Capital Management Inc. raised its holdings in shares of Medpace by 2.6% in the 3rd quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock worth $127,060,000 after purchasing an additional 9,592 shares during the period. Finally, FMR LLC lifted its stake in shares of Medpace by 11.8% in the 3rd quarter. FMR LLC now owns 231,019 shares of the company’s stock valued at $77,114,000 after purchasing an additional 24,362 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $354.10 on Friday. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The stock’s 50-day simple moving average is $343.61 and its 200-day simple moving average is $350.38. The firm has a market cap of $11.01 billion, a price-to-earnings ratio of 31.01, a PEG ratio of 1.79 and a beta of 1.36.

Analyst Ratings Changes

MEDP has been the subject of a number of research analyst reports. Truist Financial dropped their target price on shares of Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Redburn Atlantic assumed coverage on shares of Medpace in a report on Monday, October 14th. They set a “buy” rating and a $404.00 target price on the stock. William Blair reiterated an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Finally, Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.